Premium
Acute myeloid leukaemia secondary to treatment with capecitabine for metastatic colorectal cancer
Author(s) -
Shapiro Susan,
Hughes George,
AlObaidi Magda Jabbar,
O’Reilly Eamon,
Ramesh Subramanian,
Smith Jason,
Ahmad Riz,
Dawson Charlotte,
Riddle Pippa,
Sekhar Mallika
Publication year - 2007
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2007.00864.x
Subject(s) - capecitabine , medicine , colorectal cancer , metastatic breast cancer , oncology , cancer , myeloid leukaemia , breast cancer , adjuvant
A 63‐year‐old woman was diagnosed with acute myelo‐monocytic leukaemia, associated with MLL gene rearrangement, 16 months after completion of oral capecitabine for metastatic colon cancer. Capecitabine, recommended for use in metastatic breast and colon cancer and more recently as adjuvant treatment of colon cancer, has not previously been reported to be associated with secondary cancer.